Home
OGN
OGN News

Latest Organon & Co. (OGN) News on June 2, 2025

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection

Business Wire

6 days ago

US Food and Drug Administration (FDA) Grants Interchangeability Designation to Samsung Bioepis and Organon HADLIMA™ (adalimumab-bwwd) Injection

Argus Research

20 days ago

OGN: Rating decreased to a HOLD

CEO & Director of Organon Picks Up 14% More Stock

Simply Wall St.

24 days ago

CEO & Director of Organon Picks Up 14% More Stock

Organon (NYSE:OGN) Reports Decreased Earnings Affecting Investor Sentiment

Simply Wall St.

a month ago

Organon (NYSE:OGN) Reports Decreased Earnings Affecting Investor Sentiment

Organon & Co. (NYSE:OGN) Goes Ex-Dividend Soon

Simply Wall St.

a month ago

Organon & Co. (NYSE:OGN) Goes Ex-Dividend Soon

Argus Research

a month ago

Daily – Vickers Top Buyers & Sellers for 05/07/2025

Argus Research

a month ago

OGN: Lowering target price to $10.00

Organon price target lowered to $10 from $11 at BofA

TipRanks

a month ago

Organon price target lowered to $10 from $11 at BofA

Argus Research

a month ago

OGN: What does Argus have to say about OGN?

Argus Research

2 months ago

OGN: Lowering target price to $12.00

Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors

Business Wire

2 months ago

Organon Appoints Ramona A. Sequeira to the Company’s Board of Directors

Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025

Business Wire

2 months ago

Organon To Report First Quarter 2025 Results and Host Conference Call on May 1, 2025

Argus Research

2 months ago

OGN: Lowering target price to $13.00

Why Organon (OGN) Could Beat Earnings Estimates Again

Zacks

2 months ago

Why Organon (OGN) Could Beat Earnings Estimates Again

Argus Research

2 months ago

OGN: What does Argus have to say about OGN?

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

Business Wire

2 months ago

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Business Wire

2 months ago

European Medicines Agency (EMA) Validates Henlius and Organon Filing for Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Argus Research

2 months ago

OGN: Lowering target price to $16.00

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

Business Wire

3 months ago

New Analysis of Organon’s VTAMA® (tapinarof) cream, 1% Phase 3 Data Shows Atopic Dermatitis Disease Activity Remained Low After Treatment-Free Interval in Adults and Children 2 Years of Age and Older

Argus Research

3 months ago

OGN: Lowering target price to $15.00

Argus Research

3 months ago

OGN: Raising target price to $17.00

Argus Research

3 months ago

OGN: What does Argus have to say about OGN?

Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Simply Wall St.

4 months ago

Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Organon Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.

4 months ago

Organon Full Year 2024 Earnings: EPS Misses Expectations

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024

Business Wire

4 months ago

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2024

Argus Research

4 months ago

OGN: Lowering target price to $16.00

Argus Research

4 months ago

OGN: What does Argus have to say about OGN?

An excellent week for Organon & Co.'s (NYSE:OGN) institutional owners who own 83% as one-year returns inch higher

Simply Wall St.

4 months ago

An excellent week for Organon & Co.'s (NYSE:OGN) institutional owners who own 83% as one-year returns inch higher

Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025

Business Wire

4 months ago

Organon To Report Fourth Quarter and Full Year 2024 Results and Host Conference Call on February 13, 2025

Argus Research

4 months ago

OGN: What does Argus have to say about OGN?

Argus Research

5 months ago

OGN: What does Argus have to say about OGN?

Argus Research

5 months ago

OGN: Lowering target price to $15.00

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Business Wire

5 months ago

Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference

Argus Research

6 months ago

OGN: What does Argus have to say about OGN?

FDA approves Organon’s VTAMA cream, 1% for the treatment for AD

TipRanks

6 months ago

FDA approves Organon’s VTAMA cream, 1% for the treatment for AD

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Business Wire

6 months ago

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Argus Research

6 months ago

OGN: What does Argus have to say about OGN?

Argus Research

6 months ago

OGN: Lowering target price to $16.00

Argus Research

6 months ago

OGN: Raising target price to $17.00

Argus Research

7 months ago

OGN: Rating decreased to a HOLD

Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem

Simply Wall St.

7 months ago

Organon's (NYSE:OGN) Earnings Are Weaker Than They Seem

Argus Research

7 months ago

OGN: Lowering target price to $18.00

Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Simply Wall St.

7 months ago

Earnings Update: Organon & Co. (NYSE:OGN) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Business Wire

7 months ago

Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Simply Wall St.

7 months ago

Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28

Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023)

Simply Wall St.

7 months ago

Organon Third Quarter 2024 Earnings: EPS: US$1.39 (vs US$0.23 in 3Q 2023)

Organon Reports Results for the Third Quarter Ended September 30, 2024

Business Wire

7 months ago

Organon Reports Results for the Third Quarter Ended September 30, 2024

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Business Wire

7 months ago

US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

GlobeNewswire

7 months ago

Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Pediatrix Medical Group (MD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Zacks

7 months ago

Pediatrix Medical Group (MD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Zacks

8 months ago

Organon (OGN) Loses -9.91% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024

Business Wire

8 months ago

Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024

Argus Research

8 months ago

OGN: Lowering target price to $19.00

Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands

CNW Group

8 months ago

Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established Brands

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Business Wire

8 months ago

Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11

Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada

CNW Group

8 months ago

Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in Canada

Are Options Traders Betting on a Big Move in Organon (OGN) Stock?

Zacks

8 months ago

Are Options Traders Betting on a Big Move in Organon (OGN) Stock?

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

GlobeNewswire

8 months ago

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Business Wire

8 months ago

Organon to Acquire Dermavant including its Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%

Argus Research

9 months ago

OGN: What does Argus have to say about OGN?

Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?

Zacks

9 months ago

Should WisdomTree U.S. SmallCap Dividend ETF (DES) Be on Your Investing Radar?

Argus Research

9 months ago

OGN: What does Argus have to say about OGN?

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

Business Wire

9 months ago

Organon & Lilly Expand Migraine Commercialization Agreement to 11 Additional Markets

Investors Shouldn't Be Too Comfortable With Organon's (NYSE:OGN) Earnings

Simply Wall St.

10 months ago

Investors Shouldn't Be Too Comfortable With Organon's (NYSE:OGN) Earnings

Organon Second Quarter 2024 Earnings: EPS: US$0.76 (vs US$0.95 in 2Q 2023)

Simply Wall St.

10 months ago

Organon Second Quarter 2024 Earnings: EPS: US$0.76 (vs US$0.95 in 2Q 2023)

Organon Reports Results for the Second Quarter Ended June 30, 2024

Business Wire

10 months ago

Organon Reports Results for the Second Quarter Ended June 30, 2024

Do Options Traders Know Something About Organon (OGN) Stock We Don't?

Zacks

10 months ago

Do Options Traders Know Something About Organon (OGN) Stock We Don't?

Organon & Co. (NYSE:OGN) is largely controlled by institutional shareholders who own 79% of the company

Simply Wall St.

10 months ago

Organon & Co. (NYSE:OGN) is largely controlled by institutional shareholders who own 79% of the company

Organon (OGN) Upgraded to Strong Buy: What Does It Mean for the Stock?

Zacks

10 months ago

Organon (OGN) Upgraded to Strong Buy: What Does It Mean for the Stock?

Argus Research

10 months ago

OGN: Rating increased to a HOLD

Argus Research

a year ago

OGN: What does Argus have to say about OGN?

Argus Research

a year ago

OGN: What does Argus have to say about OGN?

Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024

Business Wire

a year ago

Organon To Report Second Quarter 2024 Results and Host Conference Call on August 6, 2024

Argus Research

a year ago

OGN: What does Argus have to say about OGN?

Do Options Traders Know Something About Organon (OGN) Stock We Don't?

Zacks

a year ago

Do Options Traders Know Something About Organon (OGN) Stock We Don't?

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

Business Insider

a year ago

US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia

The Best Woody Perfume For Women

Insider Monkey

a year ago

The Best Woody Perfume For Women

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Reuters

a year ago

Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase

Insider Monkey

a year ago

Best Date Night Fragrance in 2024

France's Macron calls snap legislative elections after EU poll blow

AFP

a year ago

France's Macron calls snap legislative elections after EU poll blow

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

Investor's Business Daily

a year ago

Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events

Toronto Pearson conducts annual full-scale emergency exercise

CNW Group

a year ago

Toronto Pearson conducts annual full-scale emergency exercise

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

The Wall Street Journal

a year ago

European Union Vote Delivers Shift to Right, in Blow to French and German Governments

Organon (OGN) Just Overtook the 20-Day Moving Average

Zacks

a year ago

Organon (OGN) Just Overtook the 20-Day Moving Average

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

Business Wire

a year ago

European Medicines Agency (EMA) Validates Henlius and Organon Filings for Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14

Organon Announces Pricing of $1.0 Billion Senior Notes Offering

Business Wire

a year ago

Organon Announces Pricing of $1.0 Billion Senior Notes Offering

Organon Announces Proposed $1.0 Billion Senior Notes Offering

Business Wire

a year ago

Organon Announces Proposed $1.0 Billion Senior Notes Offering

Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Simply Wall St.

a year ago

Organon (NYSE:OGN) Will Pay A Dividend Of $0.28

Organon First Quarter 2024 Earnings: EPS: US$0.79 (vs US$0.70 in 1Q 2023)

Simply Wall St.

a year ago

Organon First Quarter 2024 Earnings: EPS: US$0.79 (vs US$0.70 in 1Q 2023)

What Makes Organon (OGN) a New Buy Stock

Zacks

a year ago

What Makes Organon (OGN) a New Buy Stock

Organon Reports Results for the First Quarter Ended March 31, 2024

Business Wire

a year ago

Organon Reports Results for the First Quarter Ended March 31, 2024

Earnings Preview: Organon (OGN) Q1 Earnings Expected to Decline

Zacks

a year ago

Earnings Preview: Organon (OGN) Q1 Earnings Expected to Decline

Argus Research

a year ago

OGN: Raising target price to $17.00

Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024

Business Wire

a year ago

Organon To Report First Quarter 2024 Results and Host Conference Call on May 2, 2024

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

Business Wire

a year ago

Phase 3 Comparative Clinical Study of Prolia® and Xgeva® (denosumab) Biosimilar Candidate HLX14 Met Primary Endpoints

On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health

CNW Group

a year ago

On International Women's Day, Organon Canada is encouraging businesses to Invest in HER and help address gender inequities through women's health

Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary

Business Wire

a year ago

Organon Announces HADLIMA™ (adalimumab-bwwd) Has Been Exclusively Selected by the US Department of Veterans Affairs (VA), Replacing HUMIRA on Its National Formulary

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023

Business Wire

a year ago

Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2023

Landstar System, Inc. (NASDAQ:LSTR) Q4 2023 Earnings Call Transcript

Insider Monkey

a year ago

Landstar System, Inc. (NASDAQ:LSTR) Q4 2023 Earnings Call Transcript

Earnings Preview: Ares Management (ARES) Q4 Earnings Expected to Decline

Zacks

a year ago

Earnings Preview: Ares Management (ARES) Q4 Earnings Expected to Decline

Share on Social Networks: